EODData

MEMBERSHIP REGISTER LOG IN

FRA, 4A3: immatics biotechnologies GmbH

22 May 2026
LAST:

9.450

CHANGE:
 0.09		OPEN:
9.450		HIGH:
9.450		ASK:
0.000		VOLUME:
0
CHG(%):
0.94		PREV:
9.540		LOW:
9.450		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 May 269.4509.4509.4509.4500
21 May 269.5409.5409.5409.5400
20 May 269.1209.3359.1209.3350
19 May 269.0109.0109.0109.0100
18 May 269.3509.3509.3509.3500
15 May 269.4909.4909.4909.4900
14 May 269.1059.1059.1059.1050
13 May 269.5859.5859.5859.5850
12 May 269.6909.6909.6909.6900
08 May 269.3759.3759.3759.3750

PROFILE

Name:immatics biotechnologies GmbH
About:Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Sector:Healthcare
Industry:Biotechnology
Address:Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
Website:https://www.immatics.com
ISIN:NL0015285941

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:27.93 
PEG Ratio:0.07 
Price to Sales:13.73 
Price to Book:2.53 
Profit Margin:-1.42 
Operating Margin:-10.53 
Return on Assets:-0.16 
Return on Equity:-0.30 
Revenue:84.76M 
Shares:121.56M 
Market Cap:1.149B 

TECHNICAL INDICATORS

MA5:9.341.2%
MA10:9.390.6%
MA20:9.430.2%
MA50:8.916.0%
MA100:8.619.7%
MA200:7.8520.4%
STO9:64.71
STO14:52.38
RSI14:48.42
WPR14:-47.62
MTM14:-0.40
ROC14:-0.04 
ATR:0.27 
Week High:9.541.0%
Week Low:9.014.9%
Month High:9.854.2%
Month Low:9.0120.4%
Year High:10.076.6%
Year Low:4.29120.2%
Volatility:16.02